Send me a link:

*Text messaging rates may apply.

 Dow Down0.42% Nasdaq Down0.52%

BioMarin Pharmaceutical Inc. (BMRN)

-NasdaqGS
59.06 Down 1.18(1.96%) 4:00PM EDT
ProfileGet Profile for:
BioMarin Pharmaceutical Inc.
770 Lindaro Street
San Rafael, CA 94901
United States - Map
Phone: 415-506-6700
Fax: 415-382-7889
Website: http://www.biomarinpharm.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:1,341

Business Summary 

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on BioMarin Pharmaceutical Inc.

Corporate Governance 
BioMarin Pharmaceutical Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 6. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 4; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Jean-Jacques Bienaim , 60
Chief Exec. Officer and Director
1.95M9.65M
Mr. Daniel K. Spiegelman B.A., M.B.A. , 55
Chief Financial Officer and Exec. VP
741.00K1.26M
Dr. Robert A. Baffi Ph.D., 59
Exec. VP of Technical Operations
656.00K6.42M
Mr. G. Eric Davis , 43
Sr. VP, Sec. and Gen. Counsel
616.00K1.77M
Dr. Henry J. Fuchs M.D., Ph.D., 56
Chief Medical Officer and Exec. VP
940.00K3.36M
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders